Welcome to our blog! This is where we share a bit more – insights, updates, and thoughts from Genovis. Take a look around and see what you find.
Search post
Category
A recent study published on bioRxiv (Kadavá et al., 2026) sheds new light on the remarkable binding properties of AlligBAITOR — revealing why it stands out as a truly universal immunoglobulin-binding tool. AlligBAITOR was shown to bind all major human antibody isotypes and subclasses — IgG1–4, IgA1–2, and IgM — with high affinity and without…
In biopharmaceutical research, antibody quality is everything. Whether you’re developing an antibody-drug conjugate (ADC), studying glycan-mediated effector function, or characterizing a therapeutic candidate, the precision and reliability of your antibody workflow directly impacts your results – and your timeline. But setting up and optimizing these workflows in-house takes significant time, resources, and specialized expertise. That’s…
A recent study published in Blood Advances demonstrates how site-specific antibody-drug conjugates (ADCs) targeting TCRVβ2 can selectively eliminate malignant T cells while sparing most healthy T cells. Using our GlyCLICK® technology, the researchers generated homogeneous anti-TCRVβ2 ADCs with defined drug-to-antibody ratios and potent anti-tumor activity both in vitro and in vivo. Patients with advanced cutaneous…
We are expanding our enzyme platform with a proprietary portfolio of precision proteases for protein analysis! We have entered into an agreement to acquire, and completed the acquisition of, 100 percent of the shares in KPL ApS (“KPL”), a Denmark‑based life science tools company with a proprietary portfolio of precision enzymes (proteases), both commercialized and…
ASMS is always an exciting opportunity to discover new science and innovative mass spectrometry workflows. Throughout the meeting, researchers from around the world will present posters and oral presentations featuring workflows supported by Genovis SmartEnzymes™. In this year’s Digested Guide to ASMS, we’ve gathered selected presentations and posters we’re especially excited to follow. We hope…
Efficient Lys-C digestion is critical for reliable protein identification in modern proteomics workflows. Missed cleavages, incomplete protein digestion, and challenging sample types can quickly reduce confidence in downstream LC–MS analysis. To address these challenges, Genovis has launched LysCERATOR™, a new Lys-C enzyme for efficient, lysine-specific protein digestion — even under demanding conditions.
A new preprint from the creators of FLASH-seq demonstrates that replacing protein-based RNase inhibitors with the synthetic, thermostable SEQURNA significantly improves sensitivity, especially in low-RNA cells, while enabling a fully DTT-free workflow.
In molecular biology, temperature control is one of those quiet essentials that makes all the difference. From snap-freezing delicate RNA to gently warming enzyme reactions, the right temperature brings consistency to every result. Thermoconductive modules have anchored molecular biology labs for years, replacing ice buckets and uneven heat blocks with stable, uniform temperature control. But…
Researchers at Roche have recently described an elegant solution to address the persistent problem of rheumatoid interference (RF) in anti-drug antibody (ADA) immunoassays. IgMBRAZOR is a unique IgM-specific protease that digests human IgM at one specific site below the CH2 domain in the heavy chain, generating homogeneous F(ab’)2 and Fc fragments. By introducing IgMBRAZOR pretreatment…
Scientists at Boehringer Ingelheim and collaborators have developed a novel method to generate antibodies with defined asymmetrical Fc glycoforms and evaluate their Fc receptor (FcγRs) binding properties. Combining enzymatic digestion and redox-mediated Fc recombination, Fc fragments with specific glycan pairings could be generated and their Fc receptor binding analyzed by surface plasmon resonance (SPR) spectroscopy.
Preserving RNA integrity is essential in molecular biology workflows, and RNase inhibitors are a critical part of that process. But if you're still relying on a traditional protein-based recombinant inhibitor, it could be costing you more than you think - in both performance and budget. Here's why it's time to switch to a smarter alternative:
Scientists at New Jersey Institute of Technology, Johnson & Johnson and collaborators have demonstrated a novel approach for mass spectrometry (MS)-based characterization of hinge-mutated antibodies. Combining the recently introduced FabRICATOR Xtra LALA enzyme with ultrafast microdroplet digestion allows for fully automated, high-throughput and efficient antibody characterization, with the entire sample preparation and MS analysis completed…
